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ABSTRACT
Osteoblasts play a critical role in the maintenance of bone mass through bone formation and regulation of bone resorption. Targeted
expression of a constitutively active engineered Gi-coupled G protein–coupled receptor (GPCR) to osteoblasts in vivo leads to severe
osteopenia. However, little is known about the role of endogenous receptor-mediated Gi signaling in regulating osteoblast function.
In this study, we investigated the skeletal effects of blocking Gi-coupled signaling in osteoblasts in vivo. This was accomplished by
transgenic expression of the catalytic subunit of pertussis toxin (PTX) under control of the collagen Ia 2.3-kb promoter. These mice,
designated Col1(2.3)
þ/PTX
þ, showed increased cortical thickness at the femoral midshaft at 12 weeks of age. This correlated with
increased periosteal bone formation associated with expanded mineralizing surface observed in 8-week-old mice of both genders. The
cancellous bone phenotype of the Col1(2.3)
þ/PTX
þ mice was sexually dimorphic, with increases in fractional bone volume at the distal
femur seen only in females. Similarly, while cancellous bone-formation rates were unchanged in males, they could not be quantified for
female Col1(2.3)
þ/PTX
þ mice owing to the disorganized nature of the labeling pattern, which was consistent with rapid formation of
woven bone. Alterations in osteoclast activity did not appear to participate in the phenotype. These data demonstrate that Gi-coupled
signaling by GPCRs endogenous to osteoblasts plays a complex role in the regulation of bone formation in a manner that is dependent
on both gender and the anatomic site within bone.  2011 American Society for Bone and Mineral Research.
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Introduction
G
protein–coupled receptors (GPCRs) are the largest family of
cell surface receptors, and as such, they mediate a host of
cellular responses. GPCRs have been very fruitful therapeutic
targets, with over 25% of drugs approved by the Food and
Drug Administration acting directly on members of this receptor
family.
(1) GPCRs continue to be common targets of newly
developed pharmaceuticals, and furthering our understanding
of the biologic role of GPCRs still holds promise for the
development of new therapeutics. Four families of Ga proteins
are critical in mediating signaling downstream of GPCR
activation: Gs,G i,G q, and G12.
(2) A role for Gs-coupled signaling
in osteoblasts in promoting trabecular bone formation and
cortical bone resorption has been described in vivo in both gain-
of-function andloss-of-function models.
(3–6)Theroleofthe other
families of Ga proteins in the regulation of skeletal homeostasis
remains less clear.
The classic downstream effector of Gi activation is the
inhibition of adenylyl cyclase,
(2) which would be expected to
antagonize Gs-mediated increases in adenylyl cyclase activity
in osteoblasts. Transgenic expression of a constitutively active
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822Gi-coupled GPCR in osteoblasts leads to marked trabecular
osteopenia,
(7) consistent with the concept of Gi-coupled
signaling opposing Gs-mediated trabecular bone formation.
However, the role of endogenous Gi-coupled receptors in
regulating osteoblast function is less clear. A range of ligands has
been shown to elicit Gi-dependent mitogenic responses from
osteoblastic cells in vitro. These ligands include fluoride,
(8)
lysophosphatidic acid,
(9) and spingosine 1-phosphate.
(10) Addi-
tionally, activation of the Gi-coupled apelin receptor stimulates
proliferation and inhibits apoptosis of human osteoblasts
in vitro.
(11,12) Such mitogenic effects may be mediated by
alternative effectors of Gi-coupled signaling such as mitogen-
activated protein kinases (MAPKs) and phosphoinoisitide-3
kinase (PI3K).
(13,14) Two candidate GPCRs have been suggested
as potential targets for osteoporosis therapeutic strontium
ranelate
(15,16): the calcium-sensing receptor (CaSR)
(17,18) and the
closely related GPRC6A.
(19) Both these GPCRs can couple with
both Gi and Gq,
(20–22) suggesting that the in vivo anabolic actions
of strontium could, at least in part, be mediated by stimulation
of Gi signaling.
Genetic manipulation of endogenous Gi-coupled GPCRs in
mice has given rise to a range of skeletal phenotypes. Recently,
the Gi-coupled serotonin receptor Htr1b has been described
as a negative regulator of osteoblast proliferation, with global
and osteoblast-specific gene deletion of Htr1b leading to
increased vertebral bone volume associated with increased
osteoblast number.
(23) The global knockout of the NPY Y1
receptor also shows increased cancellous bone volume that is
proposed to result from loss of osteoblastic Y1 expression.
(24)
Conversely, deletion of the gene encoding the Gi-coupled CB2
cannabinoid receptor led to accelerated age-related bone loss,
and a CB2-specific agonist was found to attenuate bone loss
induced by estrogen deficiency in mice.
(25) There are, of course,
limitations to interpreting phenotypes resulting from global
gene deletions, and the marked difference in the skeletal
phenotypes of the Htr1b
 /  and CB2
 /  mice may be due in
part to differences in expression of these two receptors both
within the osteoblast lineage and in other cell types. Addi-
tionally, the contexts in which osteoblasts are exposed to the
ligands for these two receptors may differ significantly.
Furthermore, if osteoblasts at different stages of the osteoblast
lineage have altered responses to Gi-coupled signaling, this
potentially could reconcile the mitogenic effects of activation
of Gi-coupled receptors on osteoblastic cells in vitro with the
restriction of osteoblast proliferation by the Gi-coupled Htr1b
in vivo.
In this study, we have pursued a strategy of osteoblast-specific
blockade of Gi-coupled signaling in order to further elucidate
the role of this signaling pathway in regulating osteoblast
function. Gi-coupled signaling is mediated by a family of Gai
subunits (Gai1,G ai2,G ai3,G ao,G az, the retinal a subunit Gat,
and the taste a subunit Gagust)
(2) and so cannot easily be
eliminated using gene-deletion technology. However, GPCR-
mediated activation of the most ubiquitous and abundant Gai
subunits (Gai1,G ai2,G ai3, and Gao) is inhibited by pertussis
toxin, and this agent therefore is used widely in vitro as a tool
to identify Gi-mediated effector responses. Here we have
used osteoblast-specific expression of the catalytic subunit of
pertussis toxin in vivo to probe the role of receptor-mediated Gi
signaling in these cells.
Materials and Methods
Mouse studies
All transgenic mouse studies were approved by and performed
in accordance with the Institutional Animal Care and Use
Committee at the Veterans Affairs Medical Center, San Francisco,
and at the University of California San Francisco. Col1(2.3)-tTA
mice (line 139) have been described previously, and hetero-
zygous Col1(2.3)-tTA mice have been shown to be indistinguish-
able from wild-type mice.
(7) We have generated the transgenic
mouse line that expresses the catalytic subunit of pertussis toxin
(PTX) under regulatory control of the tetracycline transactivator
(tTA)–responsive tetO promoter. The coding sequence for PTX
(Bordetella pertussis strain HAV; Genbank No. AJ007364.1) was
cloned into the tTA-inducible pUHG 10-3 (tetO-PTX). A purified
tetO-PTX DNA fragment was prepared and used to microinject
FVB/Noocytes.InjectionswerecarriedoutattheTransgenicCore
Facility of the UCSF-affiliated Gladstone Foundation, according
to their standard methods. Polymerase chain reaction (PCR) from
tail genomic DNA was used to screen for founders (using the
primers CCA TAG AAG ACA CCG GGA CCG and GGA ACG TCC
GGT CAG ATG GTC GA). A single founder was identified and
backcrossed with wild-type FVB/N mice for more than six
generations. TetO-PTXmice were transferred subsequently tothe
Transgenic Mouse Facility at the Veterans Affairs Medical Center,
San Francisco. The Col1(2.3)
þ/PTX
þ mice and Col1(2.3)-tTA
control littermates used in this study were generated by
crossingmiceheterozygousforthetetO-PTXtransgenewithmice
that were true breeding for the Col1(2.3)-tTA transgene. All
animals were maintained on the FVB/N background. Mice were
maintained on either standard mouse chow or, where indicated,
a diet containing 200mg/kg of doxycycline (DoxDiet, Bio-Serv,
Frenchtown, NJ, USA).
RNA extraction and RT-qPCR
Tissue samples were isolated and kept frozen in liquid nitrogen
until processing. Prior to freezing, epiphyses were removed and
bone marrow flushed from femoral bone samples. Frozen tissues
were pulverized using a biopulverizer (Biospec Products, Inc.,
Bartlesville, OK, USA), followed by RNA extraction using RNA-
STAT60 (Tel-Test, Inc., Friendswood, TX, USA) and subsequent
purification using Micro-to-Midi Total RNA Purification Kit
(Invitrogen, Carlsbad, CA, USA). cDNA was synthesized using
TaqMan Reverse Transcription Reagents (Applied Biosystems,
Inc., Foster City, CA, USA) and random hexamer primers
according to the recommendations of the manufacturer. Gene
amplification was measured with either SYBR Green or Taqman
chemistry using the ABI Prism 7300 real-time thermocycler
(Applied Biosystems, Inc.). Analysis was carried out using the SDS
software supplied with the thermocycler using both Gapdh and
L19 as the calibrator gene. In all cases, the choice of calibrator
gene did not influence the data. All data are displayed
normalized to Gapdh. Primer details are listed in the supple-
mental material.
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Left femurs from 3-, 8-, and 12-week-old mice were isolated and
cleanedofadherenttissue.BeforemCTanalysis,boneswerefixed
for 1 to 2 days in 10% neutral buffered formalin (NBF; Fisher
Scientific, Pittsburgh, PA, USA) and dehydrated in 70% ethanol.
The femurs were imaged using a vivaCT-40mCT system (Scanco
Medical AG, Bruttisellen, Switzerland). Imaging of cancellous
bone was carried out at the distal metaphysis, and imaging of
diaphyseal cortical bone was carried out at the midpoint of the
femur. All images were obtained using an X-ray energy of 55kV
withavoxelsizeof10.5mmandintegrationtimeof1000ms.Two
regions of interest (ROIs) were chosen for assessment of
cancellous bone. ROI1 specifies a volume of metaphyseal
cancellous bone from immediately adjacent to the primary
spongiosa to a distance of 1.05mm from the primary spongiosa.
ROI2 specifies a volume of metaphyseal cancellous bone at a
distance of 1.05 to 2.10mm from the primary spongiosa. These
cancellous ROIs were assessed in femurs from 8- and 12-week-
oldmiceusingaglobalthresholdingprotocol withsegmentation
valuesof0.4/1/270.Quantitativeassessmentofdiaphysealcortex
was conducted using data from 40 slices (0.42mm) at the
midfemur. Cortical bone from 3-week-old mice was assessed
using a global thresholding protocol with segmentation values
of 0.8/1/300. Segmentation values of 0.8/1/365 were used in the
assessment of cortical bone from 8- and 12-week-old mice.
Quantitative static histomorphometry
Femurs from 12-week-old mice were isolated at the time of
euthanasia and fixed in 10% NBF for 1 to 2 days and stored in
70% ethanol. Following mCT analysis, the undecalcified bone
samples were embedded in methyl methacrylate and sectioned
with Jung 2065 and 2165 microtomes (Leica, Bannockburn, IL,
USA). Osteoblast and osteoclast surfaces in the secondary
spongiosa of the distal femoral metaphysis were measured
in von Kossa/tetrachrome-stained sections with an Osteomea-
sure System (Osteometrics, Decatur, GA, USA) as described
previously.
(26)
Dynamic histomorphometry
Mice were injected with 20mg/kg of calcein (Sigma-Aldrich, St
Louis, MO, USA) 21 and 7 days before euthanasia and with
15mg/kg of demeclocycline (Sigma-Aldrich) 2 days before
euthanasia. Mice were euthanized at 8 weeks, and femurs were
isolated, fixed in 10% NBF, and stored in 70% ethanol. Following
mCTanalysis, the undecalcified bonesamples were embeddedin
methyl methacrylate. Assessment of cancellous bone was
performed on 10-mm longitudinal sections from the left femur.
Assessmentofcorticalbonewasperformedon10-mmtransverse
sections at the midpoint of the right femur. Mosaic-tiled images
were acquired at  20 magnification with a Zeiss Axioplan
Imager M1 microscope (Carl Zeiss MicroImaging, Thornwood,
NY, USA) fitted with a motorized stage. The tiled images were
stitched and converted to a single image using the Axiovision
software (Carl Zeiss MicroImaging) prior to blinded analyses
being performed using image-analysis software (Bioquant Image
AnalysisCorp.,Nashville,TN,USA).Cancellousbonewasassessed
in an irregular ROI defined by four boundaries: a line traced at a
distance of 500mm from the growth plate, two lines drawn
parallel to the cortical bone at a distance of 200mm from the
endocortical surface, and a straight line drawn perpendicular to
the bone at a distance of 1.7mm from the lowest point of the
growth plate. An average of 5.3mm
2 of cancellous bone tissue
(including marrow) was measured. The dynamic indices of bone
formation that were measured include mineralizing surface,
mineral apposition rate, and surface-based bone-formation rate
(BFR/BS).
Serum chemistry
Blood was collected from mice at the time of euthanasia and
processed in MicroTainer serum separator tubes (BD Biosciences,
San Jose, CA, USA). Serum procollagen type I amino-terminal
propeptide (PINP) and serum pyridinoline measurements were
carried out using the rat/mouse PINP EIA Kit AC-33F1 from
Immunodiagnostic Systems (Scottsdale, AZ, USA) and the
MetraBiosystems SerumPYD Kit 8019 (MetaBiosystems, Santa
Clara, CA, USA) according to manufacturers’ directions.
Statistical analysis
All data are presented as means SD. Statistical significance was
ascertained by comparison between Col1(2.3)-PTX mice and sex-
matched littermate controls using a two-tailed Student’s t tests
assuming equal variance or, where indicated, by two-way ANOVA.
Results
Generation of mice with osteoblast-specific, tetracycline-
regulated expression of the catalytic subunit of pertussis
toxin PTX
In order to allow for the temporal control of PTX expression, we
used the tetracycline transactivator (tTA) system (TetOff).
(27,28)
To obtain spatial control, TetO-PTX transgenic mice were mated
with transgenic mice expressing tTA under the control of
the osteoblast-specific Col1a1 2.3-kb promoter fragment.
(7) PTX
expression was assessed in a range of tissues from 12-week-old
double-transgenic progeny [designated Col1(2.3)
þ/PTX
þ] and
Col1(2.3)-tTA single-transgenic controls (Fig. 1A). In animals
maintained off doxycycline, expression of PTX is limited to long
bones and calvaria, with some off-target expression in the lung.
PTX expression was almost completely suppressed in mice
maintained on a diet that contained doxycycline (Fig. 1B). We
observed large variation in PTX expression levels and examined
the expression data by gender segregation (Fig. 1C). Expression
of PTX in bone from 12-week-old males was readily detectable
but much lower than that observed for females. When PTX
expression levels were assessed in younger animals (8 weeks),
they were found to be much higher than in the 12-week-old
animals, and the gender difference in expression levels was
much less pronounced (Fig. 1D).
Effects of PTX expression on growth
Col1(2.3)
þ/PTX
þ mice were consistently runted, with body
weights 70% of their sex-matched wild-type littermates at
824 Journal of Bone and Mineral Research MILLARD ET AL.weaning. After weaning, Col1(2.3)
þ/PTX
þ mice displayed healthy
weight gain, with male Col1(2.3)
þ/PTX
þ mice weights stabilizing
at around 85% of littermate controls and females at 89% of
littermate controls. Two-way ANOVA analysis of the growth
curves of male (Fig. 2A) and female (Fig. 2B) mice demonstrated
that the effect of the Col1(2.3)
þ/PTX
þ genotype on weight was
significant (p<.001). This growth phenotype can be blunted by
maintaining Col1(2.3)
þ/PTX
þ mice on a doxycycline diet [12-
week ‘‘on doxycycline’’ weights, controls versus Col1(2.3)
þ/PTX
þ:
male 27 4g versus 25 2g, n¼8, p¼.37; female 23 3g
versus 22 3g,n¼11, p¼.31], suggesting that the phenotype
depends on the expression of PTX. In addition to reduced
body weight, Col1(2.3)
þ/PTX
þ mice maintained in the absence
of doxycycline also demonstrate reduced long bone length
(Fig. 2C).
Effects of PTX expression on cortical bone
Cortical bone of Col1(2.3)
þ/PTX
þ mice maintained in the absence
of doxycycline was assessed by mCT at the femoral midshaft
Fig. 1. Col1(2.3)
þ/PTX
þ mice have bone-specific expression of PTX
that is suppressed by administration of doxycycline. PTX expression
was assessed in (A) a range of tissues isolated from 12-week-old
Col1(2.3)
þ/PTX
þ mice and littermate controls continuously maintained
in the absence of doxycycline, (B) femurs derived from 12-week-old
Col1(2.3)
þ/PTX
þ micebred and maintained eitherin theabsence(–DOXY,
n¼6) or presence (þDOXY, n¼8) of doxycycline, (C) femurs derived
from male (n¼4) and female (n¼2) 12-week-old Col1(2.3)
þ/PTX
þ mice
maintained in the absence doxycycline, and (D) femurs derived from
male (n¼6) and female (n¼6) 8-week-old Col1(2.3)
þ/PTX
þ mice main-
tained in the absence doxycycline. All data were obtained by RT-qPCR
analysis and are expressed as mean 1 SD.
ap<.05;
cp<.001.
Fig. 2. Male and female Col1(2.3)
þ/PTX
þ mice are consistently smaller
than sex-matched littermate controls and have shorter femoral lengths.
Postweaning body weights of (A) male and (B) female Col1(2.3)
þ/PTX
þ
mice and littermate controls (n 6 per group). (C) Femoral lengths
measured following killing at 3 weeks (n 5), 8 weeks (n 10), and
12 weeks of age (n 7). All data are mean 1 SD. Statistical significance
ascertained compared with age- and sex-matched controls.
ap<.05;
bp<.01;
cp<.001.
Gi-COUPLED SIGNALING RESTRICTS BONE FORMATION Journal of Bone and Mineral Research 825(Fig. 3). In young animals (3 weeks old), both the tissue volume
and the cortical thickness were decreased in Col1(2.3)
þ/PTX
þ
mice, consistent with their smaller stature. However, in older
animals, the proportional difference in tissue volume between
control and Col1(2.3)
þ/PTX
þ mice was lessened, and at 12 weeks
of age, cortical thickness actually was greater in Col1(2.3)
þ/PTX
þ
mice than in controls (Fig. 3B). This phenomenon, which was
observed in both male and female mice, was further examined
by dynamic histomorphometry in 8-week-old animals. The
dynamic labeling protocol for the 8-week-old mice was devised
prior to full characterization of the femoral midshaft phenotype
in younger animals and was designed to cover as broad a
developmental period as possible. A dramatic increase in the
periosteal bone-formation rate (BFR/BS) resulting from increased
mineralizing surface was observed in Col1(2.3)
þ/PTX
þ mice when
assessed using a 5-day labeling interval between a calcein label
Fig. 3. Adult Col1(2.3)
þ/PTX
þ mice have increased cortical thickness associated with increased periosteal bone formation. (A) Cortical tissue volume and
cortical thickness were assessed by mCT at the midshaft of femurs isolated from male (solid bars) and female (striped bars) mice at 3 weeks (n 5), 8 weeks
(n 10), and12 weeksofage (n 7). Alldataaremean 1 SD. Statisticalsignificanceascertainedcomparedwith age-and sex-matched controls.
ap<.05;
bp<.01;
cp<.001.(B) Representativeimagesofmid-diaphysealsectionsof8-week-oldfemurslabeledwithdemeclocycline2 days prior tokillingandwith
calcein at 1 and 3 weeks prior to killing. Higher-power images are provided of the lateral, anterior, medial, and posterior periosteal surfaces. Scale bars in
yellow are 500mm. Scale bars in red are 50mm.
Table 1. Periosteal Dynamic Histomorphometric Measurements Performed on Col1(2.3)
þ/PTX
þ Mice and Littermate Controls at the
Femoral Midshaft
Mice MS/BS (%) MAR (mm/day) BFR/BS (mm
3/mm
2/day)
Male, control 50 7 2.6 0.4 1.3 0.3
Male, Col1(2.3)
þ/PTX
þ 75 13
c 2.7 0.6 2.0 0.6
b
Female, control 45 5 2.6 0.5 1.2 0.3
Female, Col1(2.3)
þ/PTX
þ 73 15
c 2.7 0.7 2.0 0.8
a
Note: Measurements of percent mineralizing surface (MS/BS), mineral apposition rate (MAR), and bone-formation rate (BFR/BS) were performed on
femurs of 8-week-old mice, male (n¼10) and female (n¼8). Statistically significant changes relative to the corresponding littermate control group are
indicated by
ap<.05,
bp<.01, or
cp<.001.
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2 days before euthanasia (Table 1). Similar results were observed
using a longer labeling interval (calcein label given at 5 and
7 weeks of age; data not shown). Fluorescence microscopy
of femoral midshaft sections demonstrate that the pattern of
periosteal bone formation is significantly altered in Col1(2.3)
þ/
PTX
þ mice (Fig. 3B). Mineralizing surface in control mice was
restricted primarily to the lateral and anterior surfaces of the
femoral midshaft, with little or no active bone formation on
the medial and posterior surfaces. In contrast, Col1(2.3)
þ/PTX
þ
mice displayed an expanded mineralizing surface with active
bone formation evident around the entire circumference of
the bone. While there are clear regional differences in mineral
apposition rate (MAR) on the periosteal surfaces of both control
and Col1(2.3)
þ/PTX
þ bones, the aggregate MAR across the entire
periosteal surface was not altered in Col1(2.3)
þ/PTX
þ mice.
Quantitation of endocortical bone formation gave less striking
results. While there was a suggestion of increased endocortical
mineralizing surface (significant only in females) and decreased
endocortical MAR (significant only in males), no change in
endocortical BFR/BS was observed (Table 2).
Effects of PTX expression on cancellous bone structure
To assess cancellous bone mass in Col1(2.3)
þ/PTX
þ mice, femurs
from 12-week-old mice were examined using both mCT and
histomorphometry. Assessment using mCT was used initially to
evaluate a metaphyseal trabecular ROI immediately adjacent to
the primary spongiosa: ROI1 (Fig. 4A). The cancellous tissue
volume within this region showed a small, statistically significant
decrease in Col1(2.3)
þ/PTX
þ mice of both genders, consistent
with the smaller size of these animals. Male Col1(2.3)
þ/PTX
þ mice
displayed a reduction in fractional bone volume (BV/TV) in
ROI1, whereas female Col1(2.3)
þ/PTX
þ mice show no significant
change(Fig.4A).Histomorphometricanalysisrevealedadifferent
story, with male Col1(2.3)
þ/PTX
þ mice displaying no change in
BV/TV, whereas female Col1(2.3)
þ/PTX
þ mice displayed a striking
increase in BV/TV associated with increased trabecular number,
decreased trabecular spacing, and no changein trabecular width
(Fig. 4C). When considering the contradictory nature of the mCT
evaluation of ROI1 and histomorphometric analysis of the same
bones, it was noted that the histomorphometric region of
analysiswasplacedfurtherfromthegrowthplatethanmCTROI1.
To account for this, the mCT scans were retrieved, and an
ROI further from the growth plate, ROI2, was evaluated. The
assessment of ROI2 was found to concur with the histomorpho-
metric assessment. Male Col1(2.3)
þ/PTX
þ mice showed no
significant changes in BV/TV, and female Col1(2.3)
þ/PTX
þ mice
had strikingly increased BV/TV (Fig. 4A). The female-specific
increase in BV/TV in ROI2 was associated with an increase
in trabecular number, decrease in trabecular spacing, and
increased connectivity density (Fig. 4B). In summary, the
phenotype of Col1(2.3)
þ/PTX
þ mice with respect to cancellous
bone volume was found to be both sexually dimorphic and
dependent on the metaphyseal trabecular ROI chosen for
analysis.
Effects of PTX expression on osteoblasts and
bone formation
Consistent with the sexually dimorphic changes in cancellous
bone mass, levels of serum N-terminal propeptide of type I
procollagen (PINP), a marker of bone formation, were increased
in female Col1(2.3)
þ/PTX
þ mice compared with littermate
controls,butnotinmaleCol1(2.3)
þ/PTX
þmice(Fig.5C).However,
sexually dimorphic changes observed in osteoblast surface did
not correlate with changes in cancellous bone mass, with female
Col1(2.3)
þ/PTX
þ mice showing decreased osteoblast surface and
males showing increased osteoblast surface (Fig. 5A). These
changes in osteoblast surface also did not correlate with the lack
of alteration in the expression of osteoblast marker genes Runx2,
osterix, and osteocalcin in RNA isolated from 8-week-old femurs
(data not shown). Curiously, both male and female Col1(2.3)
þ/
PTX
þ mice demonstrated an increase in osteoid volume.
Quantifiable amounts of osteoid are not typically observed in
the mouse, and all control animals were assigned a minimum
detectable osteoid volume of 0.1%, whereas osteoid was readily
quantifiable in all samples of Col1(2.3)
þ/PTX
þ mice (Fig. 5B).
Alterations in cellular morphology also were noted in both male
and female Col1(2.3)
þ/PTX
þ mice. Col1(2.3)
þ/PTX
þ mice dis-
playedanotableincreaseinplumposteoblast-likecellsthatwere
not directly associated with the bone surface both in the primary
spongiosa (Fig. 5F) and in the secondary spongiosa (Fig. 5F).
This was particularly evident in the primary spongiosa, where
in Col1(2.3)
þ/PTX
þ mice marrow elements were never observed
within 100mm of the growth plate. Marrow elements were
readily observed in this region in control mice.
To assess whether the increased cancellous bone mass
observed in female Col1(2.3)
þ/PTX
þ mice could be due to
increased osteoblast activity, dynamic histomorphometry was
Table 2. Endocortical Dynamic Histomorphometric Measurements Performed on Col1(2.3)
þ/PTX
þ Mice and Littermate Controls at the
Femoral Midshaft
Mice MS/BS (%) MAR (mm/day) BFR/BS (mm
3/mm
2/day)
Male, control 63 7 1.2 0.3 0.7 0.2
Male, Col1(2.3)
þ/PTX
þ 68 10 0.9 0.2
a 0.6 0.1
Female, control 77 11 1.5 0.3 1.2 0.4
Female, Col1(2.3)
þ/PTX
þ 88 6
a 1.4 0.3 1.2 0.3
Note: Measurements of percent mineralizing surface (MS/BS), mineral apposition rate (MAR), and bone-formation rate (BFR/BS) were performed on
femurs of 8-week-old mice, male (n¼10) and female (n¼8). Statistically significant changes relative to the corresponding littermate control group are
indicated by
ap<.05.
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Col1(2.3)
þ/PTX
þ bones could not be quantified owing to the
disorganizednatureofboneformation,whichdisplayedadiffuse
labeling pattern consistent with the rapid formation of woven
bone (Fig. 5D). Polarized light microscopy confirmed the
presence of short, disorganized collagen fibers in female
Col1(2.3)
þ/PTX
þ cancellous bone compared with cancellous
bone from control littermates (Fig. 5D). In contrast, expression of
PTX produced no alteration in BFR/BS in male mice (control
0.68 0.13mm
3/mm
2/d versus Col1(2.3)
þ/PTX
þ 0.77 0.12mm
3/
mm
2/d,n¼5,p¼.30).Curiously,theincreasedosteoblastactivity
demonstrated in female Col1(2.3)
þ/PTX
þ mice in vivo could not
be replicated in in vitro cultures of primary bone marrow stromal
cells (BMSCs) from these mice, as assessed by the number of
alkaline phosphatase– and Von Kossa–stained colonies and
osteoblast marker gene expression (data not shown). Neither
was there a change in the in vitro behavior of male Col1(2.3)
þ/
PTX
þ BMSCs (data not shown).
It has been shown previously that treatment of mice with the
serotonin synthesis inhibitor pCPA leads to increased expression
of cyclin D1, cyclin D2, and cyclin E1 in bone, presumably
through reducing activation of the Gi-coupled Htr1b receptor in
osteoblasts.
(23) Consequently, we examined the expression of
these genes in RNA isolated from 8-week-old femurs in our
model of osteoblast-specific Gi signaling blockade. Cyclin D1was
significantly increased in both male and female Col1(2.3)
þ/PTX
þ
mice, cyclin D2 showed a trend toward being increased in
females, and no change was seen in cyclin E1 (Fig. 5E).
Fig. 4. Col1(2.3)
þ/PTX
þ mice display a sexually dimorphic cancellous bone phenotype. (A) Cancellous bone was assessed by mCT at two volumetric
regions of interest, ROI1 and ROI2, of 12-week-old femurs. Tissue volume and fractional bone volume data are provided for both regions. (B) Structural
parameters derived from the analysis of mCT ROI2. (C) Histomorphometric analysis of 12-week-old femurs. All data are mean 1 SD; n 9 per group.
Statistical significance ascertained compared with age- and sex-matched controls.
ap<.05;
bp<.01;
cp<.001. BV/TV¼bone volume/tissue volume;
Tb.N¼trabecular number; Tb.Sp¼trabecular spacing; Conn.Den¼connectivity density; Tb.W¼trabecular width.
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on osteoclasts
Whereas osteoblasts have a well-appreciated role in regulating
osteoclast number and activity, we saw little evidence suggest-
ing that blockade of Gi-coupled signaling in osteoblasts has
downstream effects on osteoclasts. Histomorphometry revealed
an increase in osteoclast surface only in Col1(2.3)
þ/PTX
þ males
(Fig. 6A). However, levels of serum pyridinoline cross-links, a
marker of bone resorption, were unaltered in both male and
female Col1(2.3)
þ/PTX
þ mice (Fig. 6B). RANKL and osteoprote-
gerin (OPG) are important factors expressed by osteoblasts that
regulate osteoclastogenesis.
(29) Expression of RANKL and OPG
and the ratio of RANKL/OPG expression remain unchanged by
osteoblast-specific PTX expression in bone from 8-week-old
femurs (Fig. 6C and data not shown). Similarly, expression of
the calcitonin receptor, a gene highly expressed in osteoclasts,
is unchanged in bone from Col1(2.3)
þ/PTX
þ mice (Fig. 6D).
Discussion
For several decades, sensitivity to pertussis toxin has been the
‘‘gold standard’’ in determining the involvement of receptor-
activated Gi signaling in in vitro assays. Here we describe the
osteoblast-specific, tetracycline-regulated expression of the S1
catalytic subunit of pertussis toxin for the purpose of probing
the role of this signaling pathway in vivo. Previously, transgenic
Fig. 5. Female Col1(2.3)
þ/PTX
þ mice show evidence of increased osteoblast activity. (A) Osteoblast surface per bone surface (Ob.S/BS) assessed by
histomorphometry in sections of 12-week-old femurs (n 9 per group). (B) Fractional osteoid volume (OV/TV; osteoid volume/tissue volume) assessed in
12-week-old femurs (n 7 per group). (C) Serum N-terminal propeptide of type I procollagen (PINP), a marker of osteoblast activity, measured in serum
from 8-week-old animals (n¼4 per group). (D) Representative images of cancellous bone from the distal femurs of 8-week-old female mice observed
under fluorescent (Fluor) or polarized (Polar) light. Mice received injections of label at 1 week (calcein) and 2 days (demeclocycline) prior to killing. Scale
barsinredare100mm.(E)Expressionlevelinboneofcyclins:CCND1¼cyclinD1;CCND2¼cyclinD2,CCNE1¼cyclinE1.Allexpressiondatawereobtained
by RT-qPCR analysis of RNA isolated from 8-week-old femurs (n¼6 per group). All data are shown as mean 1 SD. Statistical significance ascertained
compared with age- and sex-matched controls.
ap<.05;
bp<.01. ( F) Representative images of von Kossa– and tetrachrome-stained primary spongiosa
fromthedistalfemursof12-week-oldmice.(G)RepresentativeimagesofvonKossa–andtetrachrome-stainedsecondaryspongiosafromthedistalfemurs
of 12-week-old mice. Marrow elements are marked with an asterisk. Osteoblast-like cells not associated with the bone surface are marked with an
arrowhead. Scale bars in yellow are 20mm.
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signaling in T cells,
(30) and a model for Cre-inducible PTX
expression has been demonstrated in pancreatic b cells.
(31) Our
model is unique in that it allows for the reversible regulation of
PTX expression. For this to be significant, it is imperative that
suppression of PTX expression by doxycycline is sufficient to
ablate the functional enzymatic activity of PTX. Our observation
that maintaining Col1(2.3)
þ/PTX
þ mice on a doxycycline diet
suppressesthegrowthphenotypeoftheseanimalssuggeststhat
this is the case. As in other models of in vivo PTX expression,
we saw no evidence that chronic expression of PTX negatively
affected cell health. Col1(2.3)
þ/PTX
þ mice showed normal
skeletal development and, in fact, demonstrated site-specific
increases in osteoblast activity.
Examination of the role of individual Gi-coupled GPCRs
in regulation of skeletal homeostasis has yielded evidence
suggesting that Gi signaling in osteoblasts may have either
anabolic or catabolic effects in bone. The phenotype of the
Col1(2.3)
þ/PTX
þ mouse clearly demonstrates that the predomi-
nant role of Gi-coupled signaling by endogenous receptors in
mature osteoblasts is to restrict bone formation. However,
blockade of Gi-coupled signaling by endogenous receptors does
not universally affect the bone-forming activity of all osteoblasts.
Rather, regional specificity in where bone formation was
increased was observed in Col1(2.3)
þ/PTX
þ mice. This suggests
thatosteoblastsatdifferentsitesmaybedistinguishedfromeach
other either by the complement of Gi-coupled receptors that
they express or by differential exposure to the ligands of these
receptors. In fact, this may be one mechanism by which cortical
drift, the differential regulation of bone formation at different
cortical surfaces, is normally established. The phenomenon of
cortical drift is poorly understood but is of clear importance in
determining bone shape as well as bone volume. The role of
cortical drift in regulating bone shape is recognized both during
growth
(32–34) and in response to mechanical stimuli.
(35,36)
Col1(2.3)
þ/PTX
þ mice do not have gross deformities in bone
development, patterning, or shape, but the altered pattern of
bone formation does suggest that they will develop changes in
femoral shape as they age. The effect of these changes on the
biomechanical properties of the bone remains to be investi-
gated.
Regional specificity of increases in bone formation also was
observed in cancellous bone of Col1(2.3)
þ/PTX
þ mice. Assess-
ment of the secondary spongiosa at the distal femur conducted
intwo ROIs usingmCTyielded significantly differentresults inthe
two regions. In ROI1, close to the primary spongiosa, fractional
bone volume was decreased or unchanged in Col1(2.3)
þ/PTX
þ
mice,whereasinROI2,furtherfromthegrowthplateandprimary
spongiosa, fractional bone volume was unchanged or increased
in Col1(2.3)
þ/PTX
þ mice. Our data suggest that there may be a
differential role in Gi signaling in newer bone formed in ROI1
compared with more mature bone found in ROI2. Our data also
describe a sexually dimorphic cancellous bone phenotype in
Col1(2.3)
þ/PTX
þ mice. Interpretation of this sexual dimorphism is
complicated by our observation of differential levels of PTX
expressioninbonefrommaleandfemalemice.PTXisanenzyme
and would be expected to yield complete blockade of receptor-
mediated Gi activation in osteoblasts at low levels of expression.
However, owing to difficulties in obtaining a homogeneous
population of Col1(2.3)-defined osteoblasts for biochemical
analysis, we have been unable to directly assess the efficacy
of the Gi signaling blockade. Hence we are currently unable to
conclude that osteoblast-specific Gi signaling blockade was
achieved equally in males and females. It is also unclear whether
the difference in PTX expression in males and females represents
agenuinegenderdifferenceintheactivityofthemouseCol1(2.3)
promoter. Alternatively, a sexually dimorphic response to the
expression of PTX could lead to maintenance of higher levels
of Col1(2.3) promoter activity in females but not males as the
animals age. In favor of the sexually dimorphic phenotype
resulting from a differential response to blockade of receptor-
activated Gi signaling, we offer the following observations: (1) At
8 weeks of age, the difference in expression of PTX in bone
between males and females is small, yet there is a great
difference between males and females in the uptake of calcein
labels for the assessment of bone formation. All male Col1(2.3)
þ/
PTX
þ mice had quantifiable labels, whereas all female Col1(2.3)
þ/
PTX
þ mice demonstrated smeared, disorganized label that could
not be quantified. (2) Although male Col1(2.3)
þ/PTX
þ mice did
not differ from littermate controls in their cancellous BFR/BS or
Fig. 6. Col1(2.3)
þ/PTX
þ mice show little evidence of altered osteoclast
activity. (A) Osteoclast surface per bone surface (Oc.S/BS) assessed by
histomorphometry in sections of 12-week-old femurs (n 9 per group).
(B) Serum pyridinoline cross-links, a marker of osteoclast activity, mea-
sured in sera from 8-week-old animals (n¼4 per group). (C) The RNA
expression ratio of the osteoclastogenic factor RANKL and its decoy
receptor OPG in bone. (D) Expression level of the osteoclast marker gene
calcitonin receptor (CALCR) in bone. All expression data were obtained by
RT-qPCR analysis of RNA isolated from 8-week-old femurs (n¼6 per
group). All data are shown as mean 1 SD. Statistical significance
ascertained compared with age- and sex-matched controls.
ap<.05.
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are not completely devoid of a cancellous bone phenotype.
Histology and histomorphometry of the distal femur showed
male Col1(2.3)
þ/PTX
þ mice to have increased osteoid volume
and increased number of osteoblast-like cells not directly
associated with the bone surface. Increased osteoid volume in
males in the absence of altered BFR/BS or BV/TV suggests that
there may be a role for Gi signaling promoting normal bone
mineralization. Increased osteoid volume seen in female
Col1(2.3)
þ/PTX
þ mice may be contributed to by the rapid rate
of bone formation leading to a lag in mineralization of bone
matrix.
Despite the in vivo phenotype of Col1(2.3)
þ/PTX
þ mice, we
could not demonstrate altered behavior of primary BMSC
cultures derived from these mice. The absence of correlation
between the in vivo and in vitro behavior of Col1(2.3)
þ/PTX
þ
osteoblasts could result from a number of possible causes. First,
we postulate that the Col1(2.3)
þ/PTX
þ mouse phenotype results
from the inhibition of a Gi-coupled signal in osteoblasts. If the
ligand that stimulates this signal is missing in vitro, we would
expect a loss of phenotype in vitro. We have reported previously
that Col1(2.3)
þ/Ro1
þ mice, which have osteoblast-specific
expression of a constitutively active Gi-coupled engineered
receptor, display osteopenia in vivo. However, BMSC and
calvarial cultures of cells derived from Col1(2.3)
þ/Ro1
þ mice
also do not show any overt phenotype in vitro
(7) (data not
shown). Hence neither inhibition nor activation of Gi-coupled
signaling in osteoblasts in vitro results in a phenotype, despite
significant in vivo phenotypes. This suggests that some other
component of the bone microenvironment necessary for
manifestation of the phenotypes resulting from altered Gi-
coupled signaling in osteoblasts in vivo is missing from the in
vitro culture systems.
We had hypothesized that the role of Gi signaling in
osteoblasts may be to antagonize increases in cAMP levels in
response to Gs-coupled signaling. If this were the case, blockade
of receptor-mediated Gi signaling in osteoblasts would be
expected to yield a similar phenotype to models of increased Gs
signaling in osteoblasts. The phenotypes of transgenic mouse
models with osteoblast-specific activation of Gs-coupled signal-
ing typically are characterized by increased trabecular bone
formation, marrow fibrosis, and cortical bone resorption.
(4–6) This
differs significantly from the Col1(2.3)
þ/PTX
þ model, where
increased trabecular bone formation is noted only in female
mice. While there is an expansion of osteoblast-like cells not
directly associated with the bone surface in both male and
female Col1(2.3)
þ/PTX
þ mice, this model does not display the
marked areas of marrow fibrosis observed in models of
increased Gs signaling in osteoblasts. Additionally, decreased
cortical thickness and dramatically reduced periosteal MAR and
BFR/BS in models of increased Gs signaling in osteoblasts
(5)
contrast with the increased cortical thickness, periosteal
mineralizing surface, and BFR/BS in the Col1(2.3)
þ/PTX
þ mouse.
Increased Gs-coupled signaling in osteoblasts is also classically
associated with increased RANKL expression and increased
osteoclastogenesis and activity. We saw no increase in RANKL
expression in bone and no indication of increased osteoclast
activity in Col1(2.3)
þ/PTX
þ mice. These data suggest that
while Gs-coupled signaling in osteoblasts promotes bone
formation and Gi-coupled signaling in osteoblasts restricts
bone formation, the downstream consequences of blockade
of Gi-coupled signaling in osteoblasts are not exclusively
mediated by relieving inhibition of adenylyl cyclase–mediated
production of the second-messenger cAMP.
Our data suggest that receptor-activated Gi signaling in
osteoblasts acts as a site-specific constitutive negative regulator
of boneand may be a therapeutic target. In recent years, another
class of constitutive negative regulators of bone formation, the
secreted Wnt inhibitors, has been fruitfully targeted in the search
for anabolic therapies for osteoporosis. While there are many
secreted Wnt inhibitors, they appear not to be functionally
redundant, and antagonism of a single inhibitor yields increases
in bone formation. Perhaps the same will be true for Gi-coupled
GPCRs, and identifying the full complement of Gi-coupled GPCRs
expressed in osteoblasts may reveal novel therapeutic targets.
The Gi-coupled serotonin receptor Htr1b is one such target,
and suppression of gut-derived serotonin synthesis has shown
promise in treating rodent models of postmenopausal bone
loss.
(37) Provided that the increased bone formation and bone
volume associated with the blockade of Gi-coupled signaling
can be shown to correlate with increased bone strength, it
represents a novel therapeutic target for the development of
bone anabolic therapies.
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